BLES (bovine lipid extract surfactant) / Lawson Health Research Institute, BLES Biochemicals - LARVOL DELTA

E-cigarette aerosol exposure of pulmonary surfactant impairs its surface tension reducing function. (PubMed, PLoS One) - "EC aerosols alter surfactant function through increases in minimum surface tension. This impairment may contribute to lung dysfunction and susceptibility to further injury."

Journal • Pulmonary Disease • Respiratory Diseases

LESSCOVID: London's Exogenous Surfactant Study for COVID19 (clinicaltrials.gov) - P1/2; N=20; Completed; Sponsor: Lawson Health Research Institute; Not yet recruiting ➔ Completed; Trial completion date: Jul 2021 ➔ Oct 2021; Trial primary completion date: Jan 2021 ➔ Sep 2021

Clinical • Trial completion • Trial completion date • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease • CSF2 • CSF3 • IFNG • IL10 • IL1B • IL4 • IL6 • TNFA

[VIRTUAL] Surface Tension Reduction by Peptoid-Based Exogenous Surfactants (ATS-I 2020) - "This activity was compared to mixtures of lipids without peptoids (negative control) and an animal-derived surfactant, BLES, as a positive control... It is concluded that peptoid-based surfactants are capable of surface tension reductions similar to animal derived surfactants and could therefore be developed into an alternative exogenous surfactant preparation for clinical use. Further studies are required to evaluate these surfactants in lung injury conditions such as in the presence of edematous material."

Acute Respiratory Distress Syndrome • Respiratory Diseases

LESSCOVID: London's Exogenous Surfactant Study for COVID19 (clinicaltrials.gov) - P1/2; N=20; Not yet recruiting; Sponsor: Lawson Health Research Institute

New P1/2 trial